Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 10, 2011. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The primary financial activity reported is a share buyback:
- Shares Purchased: 1,300,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,179.5 pence per share; lowest price paid was 1,164.0 pence per share.
- Treasury Holdings: The Company holds 476,017,284 shares in Treasury (8.39% of total issued share capital).
- Total Voting Rights: Including unsettled purchases, Treasury holdings represent 9.24% of total voting rights.
- Shares in Issue: 5,194,752,446 shares (excluding Treasury shares).
Material Changes
The filing reports an increase in Treasury shares following the purchase of 1,300,000 shares on February 10, 2011. No other material changes to financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is strictly a notification of a completed share repurchase and the resulting capital structure.
Investor Verification Checklist
- Verify the total cost of the 1,300,000 shares purchased based on the weighted average price between 1,164.0 and 1,179.5 pence.
- Confirm the impact of the 9.24% Treasury holding on the denominator for shareholder notification thresholds under FSA Disclosure and Transparency Rules.
- Check subsequent filings for the settlement status of the shares purchased but not yet settled at the time of this report.